A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences
Portfolio Pulse from Benzinga Insights
Over the past three months, 7 analysts have shared their insights on Neurocrine Biosciences (NASDAQ:NBIX), with ratings ranging from bullish to bearish. The average 12-month price target is $168.29, with a high of $193.00 and a low of $152.00. Recent analyst actions include maintaining or raising ratings and price targets, reflecting positive sentiment. Neurocrine Biosciences has shown strong financial performance with a 22.57% revenue growth rate, a net margin of 8.42%, and a debt-to-equity ratio of 0.21.
August 01, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have shown positive sentiment towards Neurocrine Biosciences (NASDAQ:NBIX) with an average 12-month price target of $168.29. The company has demonstrated strong financial performance with a 22.57% revenue growth rate and a net margin of 8.42%.
The positive sentiment from analysts, reflected in the raised price targets and maintained ratings, combined with the company's strong financial performance, suggests a likely short-term increase in NBIX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100